Design and characterization of nanocrystals of lovastatin for solubility and dissolution enhancement

Journal of Nanomedicine and Nanotechnology

Volumn 2, Issue 2, 2011, Pages

  Nanjwade, Basavaraj K ^a   Derkar, Ganesh K ^a   Bechra, Hiren M ^a   Nanjwade, Veerendra K ^a   Manvi, F V ^a  

^a K L E S S COLLEGE OF PHARMACY   (India)

Author keywords

Crystallinity; Formulation; Insolubility; Lipophilic; Lovastatin; Nanocrystal; Precipitation method

Indexed keywords

EID: 84875983243     PISSN: None     EISSN: 21577439     Source Type: Journal    
DOI: 10.4172/2157-7439.1000107     Document Type: Article

References (17)

1. Loftsson T, Hreinsdottir D (2005) Masson Mar. Evaluation of Cyclodextrin solubilization of drugs. Int J Pharm 302: 18-28.
2. Tufts center for the study of drug development (2001) Tufts University, Boston Mass USA: http://csdd.tufts.edu.in
3. Muller RH, Bohm BHL (1998) Nanosuspensions, in Emulsions & Nanosuspensions for the formulation of poorly soluble drugs. Muller R.H., Bentia S., and Bohm B.H.L. Eds. (Medpharm Scientific Publishers)Stuttgart, Germany.
4. Prasad N, Pudavar HE, Baba Koichi, Roy I, Ohulchansky T, et al. (2007) Method for delivering hydrophobic drugs via nanocrystal. United States Patent 0134340.
5. Deleers M, Hecq J, Fanara D, Vranckx H, Amighi K (2005) Preparation and characterization of nanocrystals of nifedipine for solubility and dissolution rate enhancement. Int J Pharm 299: 167-177.
6. Nti-Gyabaah J, Chmielowski R, Chan V, Chiw YC (2008) Solubility of lovastatin in a family of six alcohols: Ethanol, 1-propanol, 1-butanol, 1-pentanol, 1-hexanol and 1-ioctanol. Int J Pharm 359: 111-117.
7. Gande Suresh, Majunath K, Venkateswarlu, Satyanarayana V (2007) Preparation, Characterization, and in vitro, in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 8: 24.
8. Hidalgo IJ, Rhodes JR, Marietta MP, Dobson GL, Luo Y, et al. (2000) Estimation of oral bioavailability in the rat by the accelerated infusion technique. J Pharm Pharmacol 52: 957-961.
9. ICH QIA (R2) (2003) Stability testing guidelines: Stability testing of new drug substances and products. The European agency for the evaluation of medicinal products. CPMP/ICH/273/99:4-20.
10. Horter D, Dressman JB (1997) Influence of physiochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 25: 3-14.
11. Skelly JP, Buskirk V, Arbit HM, Amidon GL, Augsburger L (1993) Scale up of immediate release oral solid dosage forms. J Parenter Sci Technol 47: 52-56.
12. Galia E, Horton J, Dressman JB (1999) Albendazole generics-a comparative in vitro study. Pharm Res 16: 1871-1875.
13. Noory C, Tran N, Ouderkirk L, Brown S, Perry J (1999) Rethinking the use of water as a dissolution medium. Dissolution Technol 6: 6-7.
14. Shah VP, Noory A, Noory C, McCullough B, Clarke S, (1995) In vitro dissolution of sparingly water-soluble drug dosage forms. Int J of Pharm 25: 99-106.
15. Barzegar-Jalali M, Maleki N, Garjani A, Khandar AA, Haji-Hosseinloo M, (2002) Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique. Drug Dev Ind Pharm 28: 681-686.
16. Tang L, Khan SU, Muhmmad NA (2001) Evaluation and selection of biorelevant dissolution media for a poorly water soluble new chemical entity. Pharm Develop Technol 6: 531-540.
17. Vromans H, Eisson AC, Coenraad FL (1989) Mechanism of dissolution of drugcyclodextrin complexes. Drug Dev Ind Pharm 15: 250-255.